Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10235MR)

This product GTTS-WQ10235MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10235MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10309MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ603MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ9042MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ4387MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12165MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ1620MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ12334MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ12628MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMNITARG™
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW